crs-207

Vaccineexperimental

Clinical trial activity

11 trials · 10 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
9
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2007 (NCT00585845)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • crs-207

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05014776Phase 2Dec 31, 2021Johns Hopkins University, Lustgarten Foundation
NCT03190265Phase 2Oct 1, 2017Aduro BioTech, Bristol-Myers Squibb, Johns Hopkins University
NCT03006302Phase 2Jun 1, 2017Johns Hopkins University
NCT03175172Phase 2Jun 1, 2017Aduro BioTech, Merck
NCT03122548Phase 2Jun 1, 2017Aduro BioTech, Merck
NCT02575807Phase 1/Phase 2 (Phase 2)Jan 1, 2016Aduro BioTech, Incyte
NCT02243371Phase 2Dec 1, 2014Aduro BioTech, American Association for Cancer Research, Bristol-Myers Squibb, Johns Hopkins University, Stand Up To Cancer
NCT02004262Phase 2Jan 1, 2014Aduro BioTech
NCT01675765Phase 1Aug 1, 2012Aduro BioTech, National Cancer Institute (NCI)
NCT01417000Phase 2Sep 1, 2011Aduro BioTech, Johns Hopkins University
NCT00585845Phase 1Dec 1, 2007Anza Therapeutics, Inc.
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (10)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Aduro BioTechFor profit8622011
Johns Hopkins UniversityAcademic/Hospital5412011
Bristol-Myers SquibbFor profit2012014
MerckFor profit2012017
American Association for Cancer ResearchAcademic/Hospital1012014
Anza Therapeutics, Inc.For profit1112007
IncyteFor profit1012016
Lustgarten FoundationAcademic/Hospital1012021
National Cancer Institute (NCI)Government1012012
Stand Up To CancerAcademic/Hospital1012014
10 organizations
Page 1 / 1